Blockbuster drug Humira finally faces lower-cost rivals
After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.
biosimilar
AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.
Why The U.S. Remains The Most Expensive Market For 'Biologic' Drugs In The World
Biologic drugs, often made with the help of living organisms, are especially lucrative because they have scant competition from biosimilars, drugs akin to generics. It's a different story in Europe.
Small Savings For Drugs Made To Mimic Biotech Blockbusters
Pfizer is poised to start selling Inflectra, its version of the blockbuster rheumatoid arthritis drug Remicade. But the price of Inflectra is only 15 percent less.